NASDAQ$XENE
Xenon Pharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Xenon Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
Xenon Pharmaceuticals reported a net loss of $65.7 million for Q4 2024, an increase from $44.7 million in Q4 2023, primarily due to higher research and development expenses. The company anticipates having sufficient cash to fund operations into 2027.
- Net loss for Q4 2024 was $65.7 million, compared to $44.7 million for the same period in 2023.
- Research and development expenses increased to $59.5 million in Q4 2024 from $41.1 million in Q4 2023.
- General and administrative expenses rose to $18.0 million in Q4 2024 from $12.6 million in Q4 2023.
- Cash and cash equivalents and marketable securities stood at $754.4 million as of December 31, 2024.
Headline financials
Revenue & EPS history
Xenon Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
Xenon Pharmaceuticals anticipates a catalyst-rich period over the next 12 to 24 months, with significant advancements in its pipeline and potential commercial launch of azetukalner.
Tailwinds
- Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025, supporting NDA filing and potential commercial launch.
- First of three planned Phase 3 azetukalner MDD studies underway, with a second study on track to initiate mid-year.
- Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year.
- Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025.
- Neurocrine collaboration achieved a milestone with the initiation of a Phase 1 study of Nav1.2/Nav 1.6 inhibitor, triggering a $7.5 million milestone payment.
Headwinds
- Sherry Aulin, CFO, plans to step down by June 30, 2025, which may lead to a transition period.
- Clinical trials may not demonstrate safety and efficacy of product candidates.
- Promising preclinical or early clinical trial results may not be replicated in later clinical trials.
- Assumptions regarding planned expenditures and cash sufficiency may be incorrect.
- Regulatory agencies may impose additional requirements or delay clinical trial initiation/completion.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-1.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+0.8%
Avg return
30 days after
39%
19 / 49 earnings
Positive
+15.8%
Q2 2018
Best reaction
-17.5%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.5% | -6.1% | -11.8% | |
| Q4 2025 | -3.7% | -4.2% | +21.3% | |
| Q3 2025 | -4.9% | -7.0% | +8.5% | |
| Q2 2025 | +5.5% | +12.1% | +9.1% | |
| Q1 2025 | +2.3% | +0.7% | +5.7% | |
| Q4 2024 | -3.4% | -3.0% | -10.6% | |
| Q3 2024 | -4.8% | -9.6% | -10.5% | |
| Q1 2024 | -5.6% | -5.5% | -12.2% | |
| Q4 2023 | -2.1% | -3.8% | -10.0% | |
| Q3 2023 | -5.6% | -6.6% | +20.6% | |
| Q2 2023 | +8.6% | +6.2% | +7.9% | |
| Q1 2023 | -3.2% | -5.5% | +0.0% | |
| Q4 2022 | -5.3% | -5.9% | -9.3% | |
| Q3 2022 | -4.9% | -1.0% | +5.1% | |
| Q2 2022 | +0.1% | -4.4% | -3.3% | |
| Q1 2022 | +5.9% | +17.1% | +16.7% | |
| Q4 2021 | +3.3% | -4.6% | -3.6% | |
| Q3 2021 | -10.1% | -10.1% | -26.7% | |
| Q2 2021 | +6.3% | +5.6% | +3.9% | |
| Q1 2021 | -4.0% | -4.5% | +4.6% | |
| Q4 2020 | +8.2% | +6.6% | -4.2% | |
| Q3 2020 | -2.3% | +1.1% | -0.4% | |
| Q2 2020 | -2.1% | -3.6% | -1.9% | |
| Q1 2020 | +4.3% | -3.6% | -9.4% | |
| Q4 2019 | -9.3% | -18.7% | -10.3% | |
| Q3 2019 | +0.9% | -0.2% | +53.9% | |
| Q2 2019 | +0.6% | +4.0% | +10.2% | |
| Q1 2019 | -4.6% | -6.6% | +8.7% | |
| Q4 2018 | +7.3% | +6.3% | +18.8% | |
| Q3 2018 | -5.7% | -9.7% | -29.4% | |
| Q2 2018 | +15.8% | +23.7% | +38.4% | |
| Q1 2018 | +0.0% | -1.7% | +5.0% | |
| Q4 2017 | +6.2% | +17.3% | +22.2% | |
| Q3 2017 | -17.5% | -22.2% | -25.4% | |
| Q2 2017 | -4.8% | -7.9% | +1.6% | |
| Q1 2017 | -2.4% | -1.2% | -7.1% | |
| Q4 2016 | +0.0% | +0.0% | -54.2% | |
| Q3 2016 | -2.5% | -1.3% | -0.6% | |
| Q2 2016 | +1.5% | +3.6% | +9.6% | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | -1.7% | — | — | |
| Q2 2015 | -6.0% | — | — | |
| Q1 2015 | +0.7% | — | — | |
| Q4 2012 | +6.1% | — | — | |
| Q3 2014 | +6.1% | — | — | |
| Q4 2014 | -5.5% | — | — | |
| Q3 2013 | -9.7% | — | — | |
| Q4 2013 | -9.7% | — | — | |
| Q1 2014 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro